Vibriosis

Physical Signs:

• Hemorrhagic Septicaemia: Extensive external and internal hemorrhages, particularly at the base of fins, operculum, and ventral surface are a hallmark sign of acute vibriosis [1].
• Skin Ulcers and Lesions: External skin ulcers, focal necrosis, and erosion of the tail are characteristic of advanced infection [1].
• Dark Pigmentation: Affected fish exhibit abnormal darkening of the skin [1].
• Exophthalmos: Protruding or "pop-eye" appearance due to fluid accumulation behind the eye [1].
• Splenomegaly: Marked enlargement of the spleen observed at post-mortem [1].
• Pale Kidney: Renal discoloration indicating organ compromise [1].
• Skeletal Deformity (Lordosis): Spinal curvature reported in chronically affected fish [1].
• Organ Necrosis: Focal necrosis of liver, spleen, and kidney tissue [1].

Behavioral Changes:

• Lethargy: Reduced activity and slow, labored swimming [1].
• Loss of Appetite: Significant reduction in feed intake and associated weight loss [1].
• Erratic Swimming: Disoriented movement patterns in acutely affected fish [1].

Causative Agent: Vibrio spp. are Gram-negative, asporogenous rods that are straight or curved, typically motile via a single polar flagellum. They are mesophilic and chemoorganotrophic, with facultative fermentative metabolism. With the exception of V. cholerae and V. mimicus, Vibrio species are halophilic, commonly occurring at 30–35 ppt salinity, though their ability to thrive in estuarine environments is well documented [1]. V. anguillarum, the best-characterized fish pathogen, has an open pangenome comprising 2,038 core genes and 5,197 accessory "cloud" genes, reflecting high genomic plasticity and adaptability. Phylogenetic analysis reveals serotype-specific clustering: O1 strains display genetic homogeneity, while O2 and O3 serotypes exhibit greater divergence, influencing pathogenicity and ecological interactions [2].

Key Virulence Factors: Pathogenic Vibrio spp. produce a diverse arsenal of virulence factors including enterotoxins, haemolysins, cytotoxins, proteases, lipases, phospholipases, siderophores, and adhesive factors/haemagglutinins that allow them to adhere to fish epithelial cells, breach mucosal barriers, and colonize internal organs. V. anguillarum additionally encodes Type VI Secretion System (T6SS) components (hcp-2, vipB/mglB) and RTX toxins (rtxC). The small RNA VaRyhB plays a critical role in regulating iron homeostasis and siderophore biosynthesis, and deletion of this regulatory RNA results in reduced pathogenicity, demonstrating its importance in establishing infection [4, 6].

Transmission Methods:

• Horizontal Transmission: Water-borne transmission is the primary route. Vibrio spp. are free-living in the water column and sediment, entering fish via gill epithelium, skin abrasions, or the digestive tract during feeding. Live feed organisms such as rotifers (Brachionus spp.) and Artemia are documented carriers of V. anguillarum, V. alginolyticus, V. parahaemolyticus, V. harveyi, and other species, making larval rearing systems particularly high-risk environments [1].
• Vertical Transmission: Not well established for Vibrio spp., though environmental contamination of eggs is possible.
• Vector/Environmental Transmission: Vibrio species are ubiquitous in marine and estuarine environments. They thrive in association with zooplankton, shellfish, crustaceans, and benthic invertebrates, serving as persistent environmental reservoirs. Organic matter-enriched water in intensive aquaculture systems favors rapid Vibrio proliferation [1].

Clinical Examination: Gross lesion examination focuses on the characteristic combination of hemorrhagic septicaemia, external skin ulcers, darkened coloration, exophthalmos, splenomegaly, and pale kidney. However, clinical signs alone are not sufficient for species-level diagnosis given the broad overlap with other bacterial pathogens. Isolation of the causative agent from affected tissues (liver, spleen, kidney) is required for definitive diagnosis [1].

Laboratory Tests:

• Bacterial Culture: Vibrio spp. are routinely cultured on selective media such as thiosulfate-citrate-bile salts-sucrose (TCBS) agar. However, standard biochemical identification methods frequently fail at the species level due to the high genetic diversity and phenotypic similarity between closely related species (e.g., V. parahaemolyticus and V. alginolyticus share nearly identical 16S rRNA gene sequences) [1].
• PCR-Based Methods: Molecular identification using species-specific target genes encoding virulence factors (toxR, toxS, haemolysin, collagenase, or genes from pathogenicity islands) offers superior species-level discrimination. A TaqMan probe-based multiplex real-time PCR assay has been validated for the simultaneous detection of V. anguillarum, V. alginolyticus, V. harveyi, and V. scophthalmi in a single reaction, with 100× greater sensitivity than conventional PCR and results within one hour [4]. Real-time qPCR targeting the groEL gene effectively detects and quantifies V. alginolyticus, Listonella anguillarum (syn. V. anguillarum), and V. harveyi with detection limits as low as 48 CFU/mL [5].
• Serological Methods: Agglutination tests and ELISA targeting Vibrio-specific antigens (e.g., LPS) are used for serovar typing (particularly O1, O2, O3 for V. anguillarum) and for monitoring immune responses in vaccination trials [9].
• MALDI-TOF Mass Spectrometry: MALDI-TOF MS offers rapid, cost-effective, and automated identification of Vibrio isolates without the need for highly trained operators. Accuracy depends critically on database completeness; combined use of the Luvibase and Bruker databases has achieved successful identification of diverse Vibrio species. MALDI-TOF MS is increasingly used alongside molecular methods in routine aquaculture diagnostics [1].
• Histopathology: Tissue section examination reveals focal necrosis of liver, kidney, and spleen, with bacterial aggregates in affected tissues [1].

Current Treatments:

• Antibiotics: Oxytetracycline is historically the most widely used antibiotic in aquaculture for vibriosis, both prophylactically and therapeutically. Florfenicol is also approved for use in several major producing countries. Most Vibrio species retain sensitivity to tetracycline, oxytetracycline, chloramphenicol, and florfenicol, though sensitivity profiles vary considerably across strains and geographic regions [1]. There is currently no international uniformization of antibiotic use approval, with licensing determined by each country's legislation [1].
• Treatment Challenges: Antibiotic resistance among Vibrio species is a growing and urgent concern. Resistance genes for tetracycline, quinolones, and carbapenems have been identified in V. anguillarum strains via genomic analysis [2]. A meta-analysis of resistance profiles across Mediterranean aquaculture facilities shows an increasing trend in multidrug resistance among V. alginolyticus, V. harveyi, V. parahaemolyticus, and V. splendidus over time. Resistance inheritance commonly occurs via conjugation of resistance plasmids (R-plasmids), and horizontal gene transfer via genomic islands and integrating conjugative elements further accelerates dissemination [1]. Antibiotic residue concentrations in seafood biomass frequently exceed maximum residue limits in major producing countries, underlining the need for improved surveillance [1].
• AMR in LMICs: Across low- and middle-income countries (LMICs) in Africa and Asia, antimicrobial resistance in Vibrio species poses a particularly acute dual threat to aquaculture productivity and public health. Key AMR genes identified include blaTEM, blaOXA, blaKPC, sul1, tetA, tetB, ermB, qnrVC, aphA1, catII, strA, strB, and qnrV, found across V. parahaemolyticus, V. alginolyticus, V. vulnificus, and V. cholerae isolates from fish, shellfish, and aquatic environments. Ampicillin resistance is near-universal in many surveyed regions, with resistance to tetracycline, ciprofloxacin, and trimethoprim/sulfamethoxazole also widely reported. In African nations such as Nigeria, isolates from river environments showed resistance to doxycycline (71–89%), erythromycin (86–100%), and tetracycline (86–100%). AMR is estimated to cause US$1 billion in losses annually across LMICs from Vibrio-related disease alone. The detection of virulence genes including tdh, trh, toxR, hlyA, ctxA, and ureR across environmental isolates highlights the adaptive persistence of these strains throughout aquaculture systems [13].

Vaccines:

• Commercial Vaccines: Commercially available vibriosis vaccines include AquaVac™ Vibromax™ (for shrimp via Artemia nauplii bioencapsulation) and ALPHA JECT 3000 (PHARMAQ AS, Norway; intraperitoneal injection for adult fish). These products offer efficacy against the most common V. anguillarum serotypes and have been successfully deployed in salmonid aquaculture [1].
• Whole Cell Inactivated Vaccines: A formalin-killed V. harveyi vaccine administered intraperitoneally to marine red hybrid tilapia resulted in 87% survival post-challenge, compared to 20% in unvaccinated controls. Vaccinated fish showed significantly elevated IgM antibody titers and lysozyme activity [7].
• Feed-Based Vaccines: A field study of an oral feed-based inactivated vibriosis vaccine in cage-cultured Asian seabass demonstrated significantly enhanced innate immune responses (lysozyme activity), elevated serum and mucosal IgM levels, and improved growth performance over 16 weeks. Survival rate was 71.3% in vaccinated vs. 67.7% in non-vaccinated groups under field conditions [8].
• Bath Immunization: Atlantic cod bath-immunized with formalin-fixed V. anguillarum serotype O2a developed protective IgM-mediated immunity, providing full protection against O2a challenge and partial protection against O2b. Passive transfer of purified IgM from immunized donors protected naïve fish, confirming the protective role of antibody-mediated immunity even in species lacking classical CD4 T-cell help [9].
• Vaccine Implementation: The successful implementation of vaccination programs in Norway during the 1990s — combined with a phase-out of prophylactic antibiotic use — is regarded as a model example of how vaccination can dramatically reduce antibiotic dependence in intensive fish farming [1, 10].

Biosecurity Protocols:

• Monitoring and controlling Vibrio loads in rearing water, live feed, and broodstock using molecular surveillance tools [1].
• Careful management of live feed (Artemia, rotifers) to minimize introduction of pathogenic Vibrio strains into larval rearing systems [1].
• Early application of vaccination programs for juvenile and adult fish; bath immunization as a practical method for large-scale or larval fish where injection is not feasible [9, 10].

Farm Management Practices:

• Reducing stocking density and minimizing handling stress, which increase susceptibility to opportunistic Vibrio infection [1].
• Maintaining optimal water quality parameters including temperature, salinity, dissolved oxygen, and limiting organic matter accumulation [1].
• Developing and implementing probiotic supplementation — particularly strains capable of competitive exclusion of Vibrio spp. — as a sustainable, antibiotic-free approach to disease prevention. Bacillus velezensis and Phaeobacter spp. have demonstrated efficacy in inhibiting Vibrio biofilm formation and growth in aquaculture settings [1].
• Exploring phage therapy as a pathogen-specific, environmentally targeted intervention, particularly for species or developmental stages where vaccination is not applicable [1].
• Novel biocontrol agents such as Paratapes undulata extract have shown promise in reducing V. alginolyticus infection in tilapia, improving growth by ~284% and reducing mortality by 75% in infected groups compared to untreated infected controls, through immune modulation and direct antimicrobial activity [14].

Notable Outbreaks:

• Greece — 13-Year Aquaculture Monitoring (2010–2023): A comprehensive 13-year monitoring program tracking vibriosis in Greek marine aquaculture characterized 273 bacterial isolates from disease cases originating in eight regions and nine host species. The principal hosts were European seabass (Dicentrarchus labrax) and gilthead seabream (Sparus aurata). Vibrio harveyi was the dominant pathogen, isolated year-round from all host species and throughout all regions, with frequent co-isolation of Photobacterium damselae subsp. damselae and V. alginolyticus during summer. During spring, other species — V. lentus, V. cyclitrophicus, and V. gigantis — were relatively more abundant. Phylogenetic analysis using the mreB gene revealed high variability within the collection [3].
• Mediterranean Seabream Outbreaks: A meta-analysis of ten vibriosis outbreaks in both farmed and wild gilthead seabream in the Mediterranean Sea identified V. alginolyticus as the most frequently isolated species, followed by V. harveyi, V. splendidus, V. anguillarum, V. parahaemolyticus, and V. tubiashii. Vibrio isolates were most commonly recovered from liver, spleen, and kidney, followed by external lesions, gills, brain, eyes, gut, hepatopancreas, and blood. Interestingly, V. ichthyoenteri-like strains were isolated exclusively from asymptomatic individuals [1].
• Atlantic Salmon — Novel Vibrio sp. in Canada: A novel Vibrio species (sp. J383), related to V. splendidus with 93% genomic identity, was isolated from the internal organs of vaccinated Atlantic salmon showing clinical signs of ulcer disease at cage-sites in the North Atlantic. Infection assays demonstrated low-level mortality when administered intracelomic at 10⁷–10⁸ CFU/dose. Interestingly, disease severity was greatest at 12°C but absent at 16°C, and the pathogen persisted in the bloodstream for at least 8 weeks at cold temperatures, underscoring the threat posed by cold-adapted novel Vibrio species in high-latitude aquaculture [11].

Lessons Learned:

• The dominance of V. harveyi in Greek aquaculture — where it replaced V. anguillarum as the primary pathogen — highlights the need for ongoing, region-specific surveillance rather than reliance on historical assumptions about causative agents [3].
• The emergence of novel Vibrio species in vaccinated Atlantic salmon confirms that existing commercial vaccines may not protect against phylogenetically divergent strains, reinforcing the importance of regular pathogen characterization in each farming region [11].
• Live feed represents a critical but controllable vector for Vibrio introduction into larval systems; microbiome management of Artemia and rotifers is an important preventive lever [1].

Vibriosis Incidence:

• Over a 13-year monitoring period, vibriosis was a persistent and widespread concern across all eight surveyed marine aquaculture regions. Vibrio harveyi was prevalent year-round and across all nine host species, indicating it is the dominant pathogen in the Greek marine aquaculture sector. Seasonal patterns showed elevated co-isolations with Photobacterium damselae subsp. damselae and V. alginolyticus during warm summer months, while spring was characterized by higher diversity of Vibrio spp. including V. lentus and V. cyclitrophicus [3].
• Principal affected species: European seabass (D. labrax) and gilthead seabream (S. aurata) [3].

Economic Impact:

• While country-specific economic loss data for Greece were not quantified in the reviewed studies, the severity and frequency of outbreaks — combined with the dominance of V. harveyi as the principal agent — make vibriosis a leading constraint on aquaculture productivity in the Greek sector [3].

Treatment & Management:

• Antibiotic use follows Mediterranean patterns, with oxytetracycline and florfenicol as primary therapeutic agents. Increasing antibiotic resistance trends have been documented for V. alginolyticus and V. harveyi in Mediterranean facilities. Development and adoption of probiotics and vaccines as alternatives is ongoing [1, 3].

Vibriosis Incidence:

• Pathogenic Vibrio species are widely distributed in aquatic fish environments across sub-Saharan and North Africa. In Egypt, studies identified V. parahaemolyticus, V. alginolyticus, and V. cholerae from fish, with virulence genes including TL, TDH, and collagenase confirmed. In South Africa, V. parahaemolyticus isolates from fish (n=45, June–September 2023) carried blaTEM, blaOXA, aadA, sul1, tetA, tetB, and ermB resistance genes, with ampicillin resistance at 88.9%, erythromycin (84.4%), and tetracycline (75.6%). In Nigeria, 315 river isolates spanning V. parahaemolyticus, V. alginolyticus, V. vulnificus, V. mimicus, V. harveyi, and V. cholerae were characterized, with bla_OXA (27%), ampC (39%), bla_TEM (11%), tet39 (8%), aacC2 (24%), and aphA114% (aminoglycosides) AMR genes detected. In Tunisia, 126 fish isolates of V. alginolyticus and V. parahaemolyticus were characterized using the toxR gene [13].

Economic Impact:

• AMR-related vibriosis is estimated to cost LMICs approximately US$1 billion annually, with African aquaculture disproportionately affected due to limited diagnostic infrastructure, overreliance on selective culture methods, and poor antibiotic stewardship [13].

Treatment & Management:

• The majority of isolates in African studies demonstrated high resistance to ampicillin, with variable resistance to ciprofloxacin, nalidixic acid, and tetracycline. The emergence of multidrug-resistant strains highlights the urgent need for improved molecular surveillance tools and antibiotic stewardship programs tailored to LMIC contexts [13].

Vibriosis Incidence:

• In China, 312 shrimp-derived isolates of V. alginolyticus, V. parahaemolyticus, V. harveyi, V. cholerae, and V. campbellii were identified, with virulence genes chiA, hucR, vlhh, sero, flaA, vch, VAC, and rpsS detected. AMR genes strA, QnrV, sul2, and Int4 were identified, with streptomycin (43.8%) and QnrV (11.7%) as notable resistance determinants. In Bangladesh, V. parahaemolyticus isolates from fish and water (n=51) showed high resistance to amikacin (90.9%), cefotaxime and tetracycline (37.6–64%), with widespread multidrug resistance. In India, V. parahaemolyticus, V. vulnificus, and V. harveyi from fish and shrimp showed virulence genes tdh, tlh, dlA, vhpA, and pilF, with resistance to gentamicin (33–66%). In Thailand, V. parahaemolyticus isolates (n=74) from shellfish carried virulence genes tdh, trh, vcrD1, vcrD2, vopT, and totR, with cefotaxime resistance at 100% [13].

Economic Impact:

• Southeast Asian countries demonstrated considerably higher species richness in Vibrio isolations compared to African nations, reflecting the greater intensity of aquaculture operations and the corresponding selection pressure for AMR traits. The concentration of AMR aquaculture effluents in river systems and coastal environments creates persistent environmental reservoirs of resistant strains that threaten both aquatic animal and human health [13].

Treatment & Management:

• Consistent with global trends, ampicillin resistance is near-universal across Asian isolates. Resistance to ciprofloxacin, tetracycline, trimethoprim/sulfamethoxazole, and third-generation cephalosporins is widespread and increasing. The integration of advanced molecular diagnostics (multiplex PCR, chromogenic media) is essential for surveillance in resource-limited settings across the region [13].

Vibriosis Incidence:

• Vibrio species are the dominant bacterial pathogens affecting gilthead seabream and sea bass throughout the Mediterranean zone. V. alginolyticus was historically the most commonly isolated species, but V. harveyi has emerged as increasingly prevalent. Multiple outbreaks have been documented in coastal aquaculture facilities throughout Spain, Turkey, Italy, and North Africa [1].
• The chronic degradation of Mediterranean coastal waters — including sewage discharge, industrial effluents, and agricultural runoff — is correlated with elevated prevalence of pathogenic Vibrio species in both farmed and wild fish populations, increasing outbreak risk [1].

Economic Impact:

• Vibrio infections are a major contributor to the overall disease burden estimated at US$3–6 billion annually in global aquaculture. The Mediterranean zone represents one of the most heavily impacted regions globally due to intensive seabream and seabass production [1].